Search Results - "Kofler, D M"
-
1
Adenosine receptor A2a blockade by caffeine increases IFN-gamma production in Th1 cells from patients with rheumatoid arthritis
Published in Scandinavian journal of rheumatology (04-07-2022)“…Studies indicate that caffeine uptake may be a risk factor for rheumatoid arthritis (RA), but a definitive link between caffeine consumption and RA has not…”
Get full text
Journal Article -
2
Engagement of the B-cell antigen receptor (BCR) allows efficient transduction of ZAP-70-positive primary B-CLL cells by recombinant adeno-associated virus (rAAV) vectors
Published in Gene therapy (01-09-2004)“…Engagement of the B-cell antigen receptor (BCR) by crosslinking of the surface immunoglobulin (sIg) homodimer was studied for recombinant adeno-associated…”
Get full text
Journal Article -
3
Phase 1b trial of atacicept, a recombinant protein binding BLyS and APRIL, in patients with chronic lymphocytic leukemia
Published in Leukemia (01-04-2012)Get full text
Journal Article -
4
The Potential of Gene Transfer into Primary B-CLL Cells Using Recombinant Virus Vectors
Published in Leukemia & lymphoma (01-05-2004)“…Despite recent advances, chronic lymphocytic leukemia (CLL) as the most common leukemia remains a largely incurable disease. Modern treatment options include…”
Get full text
Journal Article -
5
Current status of immunotherapy in B cell malignancies
Published in Current drug targets (01-10-2006)“…Conventional treatment of hematologic malignancies mainly consists of chemotherapeutic agents or a combination of both, chemotherapy and monoclonal antibodies…”
Get more information
Journal Article -
6
Gene transfer preferentially selects MHC class I positive tumour cells and enhances tumour immunogenicity
Published in Cancer Immunology, Immunotherapy (01-05-2006)“…The modulated expression of MHC class I on tumour tissue is well documented. Although the effect of MHC class I expression on the tumorigenicity and…”
Get full text
Journal Article -
7
Phase 1 b trial of atacicept, a recombinant protein binding BLyS and APRIL, in patients with chronic lymphocytic leukemia
Published in Leukemia (2012)Get full text
Journal Article -
8
Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial
Published in The Lancet (British edition) (02-03-2024)“…Individuals with anti-citrullinated protein antibodies (ACPAs) and subclinical inflammatory changes in joints are at high risk of developing rheumatoid…”
Get full text
Journal Article -
9
Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia
Published in Blood (15-01-2006)“…In chronic lymphocytic leukemia (CLL), chromosomes usually evade detailed cytogenetic analyses because cells poorly respond to the traditionally used set of…”
Get full text
Journal Article -
10
A phase Ib trial of atacicept (TACI-Ig) to neutralize APRIL and BLyS in patients with refractory or relapsed B-cell chronic lymphocytic leukemia (B-CLL)
Published in Journal of clinical oncology (20-06-2007)“…Abstract only 3029 Background: B-CLL cells are resistant to apoptosis and thus exhibit prolonged survival and accumulation in vivo. Exogenously added soluble…”
Get full text
Journal Article -
11
Efficacy of Ranolazine for Treatment of Coronary Microvascular Dysfunction—A Systematic Review and Meta-analysis of Randomized Trials
Published in CJC open (Online) (01-01-2021)“…Coronary microvascular dysfunction (CMD) is a common cause of angina and exercise intolerance in patients without obstructive coronary artery disease. The…”
Get full text
Journal Article -
12
In vitro selection of viral vectors with modified tropism: the adeno-associated virus display
Published in Molecular therapy (01-07-2003)“…Improving the efficiency and specificity of gene vectors is critical for the success of gene therapy. In an effort to generate viral mutants with controlled…”
Get full text
Journal Article -
13
High incidence of new translocations in B-CLL detected by CD40L-enhanced cytogenetics (CEC): A new prognostic marker for infavorable survival outcome in patients with B-CLL
Published in Journal of clinical oncology (15-07-2004)“…Abstract only…”
Get full text
Journal Article -
14
High incidence of new translocations in B-CLL detected by CD40L-enhanced cytogenetics (CEC): A new prognostic marker for infavorable survival outcome in patients with B-CLL
Published in Journal of clinical oncology (15-07-2004)“…Abstract only…”
Get full text
Journal Article -
15
Green Fluorescent Protein-Tagged Adeno-Associated Virus Particles Allow the Study of Cytosolic and Nuclear Trafficking
Published in Journal of Virology (01-09-2005)“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text
Journal Article -
16
Engagement of the B-cell antigen receptor vectors
Published in Gene therapy (01-09-2004)Get full text
Journal Article -
17
Five Hundred Cases of Robotic Totally Endoscopic Coronary Artery Bypass Grafting: Predictors of Success and Safety
Published in The Annals of thoracic surgery (01-03-2013)“…Background Robotic technology has enabled totally endoscopic coronary artery bypass (TECAB) grafting. Little information is available on factors associated…”
Get full text
Journal Article -
18
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes
Published in Blood (15-02-2005)“…Fibromodulin (FMOD) was shown to be highly overexpressed in chronic lymphocytic leukemia (CLL) cells compared with normal B lymphocytes by gene expression…”
Get full text
Journal Article -
19
Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis
Published in Lancet neurology (01-01-2017)“…Summary Background Great heterogeneity exists in survival and the interval between onset of motor symptoms and dementia symptoms across synucleinopathies. We…”
Get full text
Journal Article -
20
MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8 + autologous T lymphocytes
Published in Experimental hematology (2006)“…Tumor-associated antigens (TAA) are the basis for antigen-specific immunotherapy. The human homolog of the murine double-minute 2 oncoprotein (MDM2) is a…”
Get full text
Journal Article